Again as reported in Fierce Biotech, GSK and Actelion have pulled the development plug on their insomnia drug, almorexant over patient tolerance conerns. This after GSK had signed a deal with Actelion in 2008 for up to $3.25 B in upfronts and milestones.
Almorexant was targeted to treat insomnia and also Alzheimer's and insomnia-related depression (it is likely inducing some of this now!). The drug had been projected by [very] eager analysts to hit peak sales of as much as $6 B annually - that's quite a Mother's little helper.
But now due to safety concerns, instead of putting people to sleep the drug itself will be laid to rest.